![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ViroPharma Announces Start of HCV-796 Phase I Program
ViroPharma Announces Start of HCV-796 Phase I Program
ViroPharma has announced that dosing has begun in the Phase I clinical trial for HCV-796, a novel polymerase inhibitor being developed as a potential new product to treat hepatitis C.
ViroPharma is conducting this Phase I clinical trial with its partner in the development of antiviral compounds targeting hepatitis C (HCV), Wyeth Pharmaceuticals, a division of Wyeth. Preclinical studies have shown that HCV-796 may be more potent than other anti-HCV compounds developed to date between the two companies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct